The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance
Open accessAbstract
Background: Data on the use of ceftolozane-tazobactam and emergence of ceftolozane-tazobactam resistance during multidrug resistant (MDR)-Pseudomonas aeruginosa infections are limited. Methods: We performed a retrospective study of 21 patients treated with ceftolozane-tazobactam for MDR-P. aeruginosa infections. Whole genome sequencing and quantitative real-time polymerase chain reaction were performed on longitudinal isolates. Results: Median age was 58 years; 9 patients (43%) were transplant recipients. Median simplified acute physiology score-II (SAPS-II) was 26. Eighteen (86%) patients were treated for respiratory tract infections; others were treated for bloodstream, complicated intraabdominal infections, or complicated urinary tract infections. Ceftolozane-tazobactam was discontinued in 1 patient (rash). Thirty-day all-cause and attributable mortality rates were 10% (2/21) and 5% (1/21), respectively; corresponding 90-day mortality rates were 48% (10/21) and 19% (4/21). The ceftolozane-tazobactam failure rate was 29% (6/21). SAPS-II score was the sole predictor of failure. Ceftolozane-tazobactam resistance emerged in 3 (14%) patients. Resistance was associated with de novo mutations, rather than acquisition of resistant nosocomial isolates. ampC overexpression and mutations were identified as potential resistance determinants. Conclusions: In this small study, ceftolozane-tazobactam was successful in treating 71% of patients with MDR-P. aeruginosa infections, most of whom had pneumonia. The emergence of ceftolozane-tazobactam resistance in 3 patients is worrisome and may be mediated in part by AmpC-related mechanisms. More research on treatment responses and resistance during various types of MDR-P. aeruginosa infections is needed to define ceftolozane-tazobactam's place in the armamentarium.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FastTree 2 – Approximately Maximum-Likelihood Trees for Large Alignments
Price, M. N., Dehal, P. S., & Arkin, A. P. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009490 · Cited by 14,894
Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03570.x · Cited by 14,449
Le Gall, J.-R. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.270.24.2957 · Cited by 7,773
Horan, T. C., Andrus, M., & Dudeck, M. A. (2008) · American Journal of Infection Control · doi:10.1016/j.ajic.2008.03.002 · Cited by 6,626
Vincent, J.-L., de Mendonca, A., Cantraine, F., Moreno, R., Takala, J., Suter, P. M., Sprung, C. L., Colardyn, F., & Blecher, S. (1998) · Critical Care Medicine · doi:10.1097/00003246-199811000-00016 · Cited by 3,463
Mash: fast genome and metagenome distance estimation using MinHash
Ondov, B. D., Treangen, T. J., Melsted, P., Mallonee, A. B., Bergman, N. H., Koren, S., & Phillippy, A. M. (2016) · Genome biology · doi:10.1186/s13059-016-0997-x · Cited by 3,373
Jacoby, G. A. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00036-08 · Cited by 2,165
Lister, P. D., Wolter, D. J., & Hanson, N. D. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00040-09 · Cited by 1,789
Deatherage, D. E., & Barrick, J. E. (2014) · Methods in Molecular Biology · doi:10.1007/978-1-4939-0554-6_12 · Cited by 1,609
Potron, A., Poirel, L., & Nordmann, P. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.03.001 · Cited by 688
Inexpensive Multiplexed Library Preparation for Megabase-Sized Genomes
Baym, M., Kryazhimskiy, S., Lieberman, T. D., Chung, H., Desai, M. M., & Kishony, R. (2015) · PLOS ONE · doi:10.1371/journal.pone.0128036 · Cited by 685
Role of mexA-mexB-oprM in antibiotic efflux in Pseudomonas aeruginosa
Li, X. Z., Nikaido, H., & Poole, K. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.9.1948 · Cited by 643
Multidrug-Resistant Pseudomonas aeruginosa : Risk Factors and Clinical Impact
Aloush, V., Navon-Venezia, S., Seigman-Igra, Y., Cabili, S., & Carmeli, Y. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.1.43-48.2006 · Cited by 617
van Duin, D., & Bonomo, R. A. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw243 · Cited by 549
Aminoglycoside Resistance in Pseudomonas aeruginosa
Poole, K. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.479-487.2005 · Cited by 470
Solomkin, J., Hershberger, E., Miller, B., Popejoy, M., Friedland, I., Steenbergen, J., Yoon, M., Collins, S., Yuan, G., Barie, P. S., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ097 · Cited by 420
Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes
Hirsch, E. B., & Tam, V. H. (2010) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.10.49 · Cited by 406
D'Argenio, D. A., Wu, M., Hoffman, L. R., Kulasekara, H. D., Déziel, E., Smith, E. E., Nguyen, H., Ernst, R. K., Larson Freeman, T. J., Spencer, D. H., et al. (2007) · Molecular Microbiology · doi:10.1111/j.1365-2958.2007.05678.x · Cited by 342
Jacobs, C., Frère, J.-M., & Normark, S. (1997) · Cell · doi:10.1016/s0092-8674(00)81928-5 · Cited by 331
Emergence of Resistance to Imipenem During Therapy for Pseudomonas aeruginosa Infections
Quinn, J. P., Dudek, E. J., DiVincenzo, C. A., Lucks, D. A., & Lerner, S. A. (1986) · Journal of Infectious Diseases · doi:10.1093/infdis/154.2.289 · Cited by 276
Berrazeg, M., Jeannot, K., Ntsogo Enguéné, V. Y., Broutin, I., Loeffert, S., Fournier, D., & Plésiat, P. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00825-15 · Cited by 268
Li, H., Luo, Y.-F., Williams, B. J., Blackwell, T. S., & Xie, C.-M. (2012) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2011.10.001 · Cited by 266
Cabot, G., Bruchmann, S., Mulet, X., Zamorano, L., Moyà, B., Juan, C., Haussler, S., & Oliver, A. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02462-13 · Cited by 247
Weldhagen, G. F., Poirel, L., & Nordmann, P. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.8.2385-2392.2003 · Cited by 231
Extended-Spectrum Cephalosporinases in Pseudomonas aeruginosa
Rodríguez-Martínez, J.-M., Poirel, L., & Nordmann, P. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01410-08 · Cited by 211
Fluoroquinolone-Resistant Pseudomonas aeruginosa: Assessment of Risk Factors and Clinical Impact
Gasink, L. B., Fishman, N. O., Weiner, M. G., Nachamkin, I., Bilker, W. B., & Lautenbach, E. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.11.029 · Cited by 206
Control of the AcrAB multidrug efflux pump by quorum‐sensing regulator SdiA
Rahmati, S., Yang, S., Davidson, A. L., & Zechiedrich, E. L. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.02773.x · Cited by 200
Impact of Multidrug-Resistant Pseudomonas aeruginosa Bacteremia on Patient Outcomes
Tam, V. H., Rogers, C. A., Chang, K., Weston, J. S., Caeiro, J., & Garey, K. W. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00207-10 · Cited by 155
Xiao, A. J., Miller, B. W., Huntington, J. A., & Nicolau, D. P. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.566 · Cited by 152
Cao, B., Wang, H., Sun, H., Zhu, Y., & Chen, M. (2004) · Journal of Hospital Infection · doi:10.1016/j.jhin.2004.03.021 · Cited by 143
Castanheira, M., Mills, J. C., Farrell, D. J., & Jones, R. N. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03681-14 · Cited by 141
Mechanisms of Quinolone Resistance in Clinical Strains of Pseudomonas aeruginosa
Jalal, S., & Wretlind, B. (1998) · Microbial Drug Resistance · doi:10.1089/mdr.1998.4.257 · Cited by 139
Hocquet, D., Nordmann, P., Garch, F. E., Cabanne, L., & Plésiat, P. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1347-1351.2006 · Cited by 136
Analysis of the Pseudomonas aeruginosa oprD gene from clinical and environmental isolates
Pirnay, J., Vos, D. D., Mossialos, D., Vanderkelen, A., Cornélis, P., & Zizi, M. (2002) · Environmental Microbiology · doi:10.1046/j.1462-2920.2002.00281.x · Cited by 122
Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality
Tumbarello, M., Repetto, E. C., Trecarichi, E. M., Bernardini, C., PASCALE, G. D., Parisini, A., Rossi, M., Molinari, M. P., Spanu, T., Viscoli, C., et al. (2011) · Epidemiology and Infection · doi:10.1017/s0950268810003055 · Cited by 120
Chandorkar, G., Huntington, J. A., Gotfried, M. H., Rodvold, K. A., & Umeh, O. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks246 · Cited by 118
Oh, H., Stenhoff, J., Jalal, S., & Wretlind, B. (2003) · Microbial Drug Resistance · doi:10.1089/107662903322762743 · Cited by 112
Fernández-Barat, L., Ferrer, M., De Rosa, F., Gabarrús, A., Esperatti, M., Terraneo, S., Rinaudo, M., Li Bassi, G., & Torres, A. (2017) · Journal of Infection · doi:10.1016/j.jinf.2016.11.008 · Cited by 99
Buehrle, D. J., Shields, R. K., Chen, L., Hao, B., Press, E. G., Alkrouk, A., Potoski, B. A., Kreiswirth, B. N., Clancy, C. J., & Nguyen, M. H. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02969-15 · Cited by 95
Self-citationPrevalence of AmpC over-expression in bloodstream isolates of Pseudomonas aeruginosa
Tam, V. H., Schilling, A. N., LaRocco, M., Gentry, L. O., Lolans, K., Quinn, J. P., & Garey, K. W. (2007) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01674.x · Cited by 71
Ceftolozane–tazobactam: A new-generation cephalosporin
Cluck, D. B., Lewis, P. O., Stayer, B., Spivey, J. M., & Moorman, J. P. (2015) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp150049 · Cited by 66
Pseudomonas aeruginosaNosocomial Pneumonia: Impact of Pneumonia Classification
Micek, S. T., Kollef, M. H., Torres, A., Chen, C., Rello, J., Chastre, J. E., Antonelli, M. M., Welte, T., Clair, B., Ostermann, H., et al. (2015) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2015.167 · Cited by 46
Malkoçoğlu, G., Aktaş, E., Bayraktar, B., Otlu, B., & Bulut, M. E. (2016) · Microbial Drug Resistance · doi:10.1089/mdr.2016.0012 · Cited by 46
Raimondi, A., Sisto, F., & Nikaido, H. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.8.2331-2339.2001 · Cited by 42
Cited by
Tamma, P. D., Heil, E. L., Justo, J. A., Mathers, A. J., Satlin, M. J., & Bonomo, R. A. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae403 · Cited by 1,191
Horcajada, J. P., Montero, M., Oliver, A., Sorlí, L., Luque, S., Gómez-Zorrilla, S., Benito, N., & Grau, S. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00031-19 · Cited by 961
How to manage Pseudomonas aeruginosa infections
Bassetti, M., Vena, A., Croxatto, A., Righi, E., & Guery, B. (2018) · Drugs in Context · doi:10.7573/dic.212527 · Cited by 746
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad428 · Cited by 740
Self-citationTreatment Options for Carbapenem-resistant Gram-negative Bacterial Infections
Doi, Y. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz830 · Cited by 652
Self-citation
Metadata
- Authors
- Haidar, G., Philips, N. J., Shields, R. K., Snyder, D., Cheng, S., Potoski, B. A., Doi, Y., Hao, B., Press, E. G., Cooper, V. S., Clancy, C. J., & Nguyen, M. H.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-02-25
- Volume
- 65
- Issue
- 1
- Pages
- 110-120
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2591044857
- Cited by
- 277
- References
- 44
- FWCI
- 12.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.